Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-000972-88
    Sponsor's Protocol Code Number:MK3475-062
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-07-10
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-000972-88
    A.3Full title of the trial
    A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
    Ensayo clínico de fase III, aleatorizado, controlado con tratamiento activo, con enmascaramiento parcial y con detección de biomarcadores, de pembrolizumab en monoterapia y en combinación con cisplatino + 5-fluorouracilo frente a placebo + cisplatino + 5-fluorouracilo como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica (UGE) avanzado
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Ph III Trial of Pembrolizumab (MK-3475), pembrolizumab+FP/XP vs. Placebo+FP/XP in Biomarker Select, Advanced Gastric or GEJ Adenocarcinoma
    Ensayo de fase III de pembrolizumab (MK 3475), pembrolizumab + FP/XP frente a placebo + FP/XP, con detección de biomarcadores, en el adenocarcinoma gástrico o de la UGE avanzado
    A.3.2Name or abbreviated title of the trial where available
    Pembrolizumab+FP/XP vs. Placebo+FP/XP in Biomarker Select, Advanced Gastric or GEJ Adenocarcinoma
    A.4.1Sponsor's protocol code numberMK3475-062
    A.5.4Other Identifiers
    Name:KeynoteNumber:-062
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMerck Sharp & Dohme de España S.A.
    B.5.2Functional name of contact pointInvestigación Clínica
    B.5.3 Address:
    B.5.3.1Street AddressC/ Josefa Valcárcel, 38
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28027
    B.5.3.4CountrySpain
    B.5.4Telephone number+34913210600
    B.5.5Fax number+34913210590
    B.5.6E-mailensayos_clinicos@merck.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namepembrolizumab
    D.3.2Product code MK-3475; SCH900475
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPEMBROLIZUMAB
    D.3.9.1CAS number 1374853-91-4
    D.3.9.2Current sponsor codeMK-3475
    D.3.9.3Other descriptive nameAnti-PD-1 monoclonal antibody
    D.3.9.4EV Substance CodeSUB167136
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Fluorouracil-GRY® 50 mg/mL solution for injection
    D.2.1.1.2Name of the Marketing Authorisation holderTEVA GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFluorouracil (5- Fluorouracil or 5-FU)
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNfluorouracil
    D.3.9.1CAS number 51-21-8
    D.3.9.3Other descriptive nameFLUOROURACIL
    D.3.9.4EV Substance CodeSUB07721MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Cisplatin Teva® 1mg/ml
    D.2.1.1.2Name of the Marketing Authorisation holderGRY-Pharma GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCisplatin
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNcisplatin
    D.3.9.1CAS number 15663-27-1
    D.3.9.3Other descriptive nameCISPLATIN
    D.3.9.4EV Substance CodeSUB07483MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCapecitabina
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNcapecitabina
    D.3.9.3Other descriptive nameCAPECITABINE
    D.3.9.4EV Substance CodeSUB12474MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/m2 milligram(s)/square meter
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNcapecitabina
    D.3.9.3Other descriptive nameCAPECITABINE
    D.3.9.4EV Substance CodeSUB12474MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/m2 milligram(s)/square meter
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNcapecitabina
    D.3.9.3Other descriptive nameCAPECITABINE
    D.3.9.4EV Substance CodeSUB12474MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/m2 milligram(s)/square meter
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Gastric or Gastroesophageal Junction Adenocarcinoma
    Gástrico o la unión gastroesofágica Adenocarcinoma
    E.1.1.1Medical condition in easily understood language
    Gastric cancer
    Cancer Gastrico
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level PT
    E.1.2Classification code 10030137
    E.1.2Term Oesophageal adenocarcinoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    In subjects with advanced gastric or GEJ adenocarcinoma treated with pembrolizumab monotherapy or a combination of pembrolizumab with chemotherapy versus chemotherapy alone, as first-line treatment in subjects with PD-L1 expression.
    Objective 1: Compare Progression Free Survival (PFS) per RECIST 1.1 as assessed by blinded central radiologists? review.
    Objective 2: Compare overall survival (OS).
    En pacientes con adenocarcinoma gástrico o de la UGE avanzado tratado con pembrolizumab en monoterapia o una combinación de pembrolizumab con quimioterapia en comparación con quimioterapia sola, como tratamiento de primera línea en pacientes con expresión de PD L1.
    Objetivo 1: Comparar la supervivencia sin progresión (SSP) conforme a los criterios RECIST 1.1 según una revisión centralizada a cargo de radiólogos sometidos a enmascaramiento.
    Objetivo 2: Comparar la supervivencia global (SG).
    E.2.2Secondary objectives of the trial
    (1) Objective: Evaluate PFS per RECIST 1.1 by local investigator review and PFS per irRECIST by blinded central radiologists? review.
    (2) Objective: Evaluate Overall Response Rate (ORR), and Duration of Response (DOR), per RECIST 1.1 as assessed by central radiologists? and local investigator review.
    (3) Objective: Evaluate the safety and tolerability profile.
    (1) Objetivo: Determinar la SSP según los criterios RECIST 1.1 mediante una revisión local por los investigadores y la SSP según los criterios irRECIST mediante una revisión centralizada por radiólogos sometidos a enmascaramiento.
    (2)Objetivo: Determinar la tasa de respuestas globales (TRG) y la duración de la respuesta (DR), según los criterios RECIST 1.1 mediante una revisión centralizada por radiólogos y una revisión local por los investigadores.
    (3) Objetivo: Evaluar el perfil de seguridad y tolerabilidad.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Merck will conduct Future Biomedical Research on DNA (blood) specimens collected during this clinical trial. Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol (as part of the main trial) and will only be conducted on specimens from appropriately consented subjects. The objective of collecting specimens for Future Biomedical Research is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer, more effective drugs, and/or to ensure that subjects receive the correct dose of the correct drug at the correct time.
    Merck llevará a cabo investigaciones biomédicas futuras con las
    muestras obtenidas específicamente con estos fines durante este ensayo
    clínico.Estas investigaciones tendrán por objeto el análisis de
    biomarcadores para abordar aspectos nuevos que no se describen en
    otras partes del protocolo (como parte del ensayo principal) y solo se
    llevarán a cabo en muestras de los sujetos que hayan otorgado el
    consentimiento correspondiente. El objetivo de la obtención de muestras
    para investigaciones biomédicas futuras consiste en estudiar e
    identificar biomarcadores que proporcionen información a los científicos
    sobre las enfermedades y sus tratamientos. El objetivo último es utilizar
    tal información para desarrollar vacunas y fármacos más seguros y
    eficaces o para garantizar que los pacientes reciban la dosis correcta del
    fármaco o la vacuna adecuados en el momento preciso.
    E.3Principal inclusion criteria
    1. Be willing and able to provide written informed consent/assent for the trial. The subject may also provide consent/assent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.
    2. Be ? 18 years of age on day of signing informed consent (or acceptable age according to local regulations, whichever is older).
    3. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
    4. Have histologically or cytologically confirmed diagnosis of locally advanced or metastatic gastric or GEJ adenocarcinoma.
    5. Be HER2/neu negative and PD-L1 positive.
    6. Have measurable disease as defined by RECIST 1.1 as determined by investigator assessment. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
    7. Have provided tumor tissue sample deemed adequate for PD-L1 biomarker analysis.
    a. Notification of eligibility must be received prior to randomization.
    b. Additional samples may be required if adequate tissue is not provided.
    8.Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the trial through 180 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. (note: Abstinence is acceptable if this is the established and preferred contraception for the subject.)
    9. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 180 days after the last dose of study therapy.
    10. Demonstrate adequate organ function as defined in Table 2. All screening labs should be performed within 10 days of treatment initiation.
    11. Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
    1. Estar dispuestos a otorgar su consentimiento o asentimiento informado por escrito para el ensayo y ser capaces de hacerlo. También podrán otorgar su consentimiento o asentimiento para la futura investigación biomédica. No obstante, podrán participar en el ensayo principal sin necesidad de hacerlo en la futura investigación biomédica.
    2. Tener 18 o más años de edad el día de la firma del consentimiento informado (o una edad aceptable conforme a las normas locales, lo que sea mayor).
    3. Presentar un estado funcional del Eastern Cooperative Oncology Group (ECOG) de 0 o 1.
    4.Tener un diagnóstico confirmado mediante histología o citología de adenocarcinoma gástrico o de la UGE localmente avanzado o metastásico.
    5. Ser HER2/neu negativo y PD L1 positivo.
    6. Presentar enfermedad mensurable conforme a los criterios RECIST 1.1, según lo determinado por el investigador. Las lesiones tumorales ubicadas en una zona previamente irradiada se considerarán mensurables siempre que se haya demostrado progresión en dichas lesiones.
    7.Haber proporcionado una muestra de tejido tumoral considerada suficiente para el análisis de biomarcadores de PD L1.
    a.Hay que notificar la elegibilidad antes de la aleatorización.
    b.Podrían necesitarse nuevas muestras en caso de que no se dispusiera de tejido suficiente.
    8. Las mujeres con capacidad de procrear deberán estar dispuestas a utilizar dos métodos anticonceptivos, estar esterilizadas quirúrgicamente o abstenerse de mantener relaciones heterosexuales durante todo el estudio y durante 180 días después de recibir la última dosis de medicación del estudio (véase la sección 5.7.2). Se entiende por mujeres en edad fértil aquellas que no están esterilizadas quirúrgicamente o no llevan más de un año sin menstruación.
    a. La abstinencia será aceptable si es el método anticonceptivo establecido y preferido de la paciente.
    9. Los varones deberán aceptar utilizar un método anticonceptivo adecuado desde la administración de la primera dosis del tratamiento del estudio hasta 180 días después de la última.
    10. Presentar una función orgánica adecuada, tal como se define en laTabla 2. Todas las pruebas analíticas de selección deberán efectuarse en los 10 días previos al comienzo del tratamiento.
    11. Las mujeres en edad fértil deberán tener una prueba de embarazo en orina o suero negativa en las 72 horas previas a la administración de la primera dosis de medicación del estudio. Cuando el resultado de la prueba en orina sea positivo o no pueda confirmarse que es negativo, será necesario hacer una prueba de embarazo en suero.
    E.4Principal exclusion criteria
    1. Has squamous cell or undifferentiated gastric cancer.
    2. Has had previous therapy for locally advanced or metastatic gastric/GEJ cancer. Subjects may have received prior neoadjuvant or adjuvant therapy as long as it was completed at least 6 months prior to randomization.
    3. Has had major surgery, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment.
    4. Has had radiotherapy within 14 days of randomization. Subjects who received radiotherapy >14 days prior to randomization must have completely recovered from any radiotherapy related AEs/toxicities.
    5. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
    6. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging at least four weeks prior to the first dose of trial treatment and neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
    7. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
    8. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
    9. Has history or evidence of interstitial lung disease or active, non-infectious pneumonitis.
    10. Has an active infection requiring systemic therapy.
    11. Has a history or current evidence of any condition (e.g. known deficiency of the enzyme dihydropyrimidine dehydrogenase [DPD]), therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject?s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
    12. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
    13. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 180 days after the last dose of trial treatment.
    14. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
    15. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
    16. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
    17. Is currently participating in and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of trial treatment.
    18. Has received a live vaccine within 30 days of planned start of study therapy.
    Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
    19. Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific subject.
    1. Presentar un cáncer gástrico epidermoide o indiferenciado.
    2. Haber recibido anteriormente tratamiento para cáncer gástrico o de la UGE localmente avanzado o metastásico. Los pacientes podrán haber recibido antes tratamiento neoadyuvante o adyuvante siempre que finalice al menos 6 meses antes de la aleatorización.
    3.Haberse sometido a un procedimiento de cirugía mayor o una biopsia abierta o haber sufrido un traumatismo importante en los 28 días previos a la aleatorización, o previsión de la necesidad de cirugía mayor durante el tratamiento del estudio.
    4. Haber recibido radioterapia en los 14 días previos a la aleatorización. Los pacientes que hayan recibido radioterapia > 14 días antes de la aleatorización deberán haberse recuperado totalmente de los AA/toxicidades relacionados con la radioterapia.
    5. Presentar otro tumor maligno conocido que esté en progresión o necesite tratamiento activo. Son excepciones el carcinoma basocelular de la piel, el carcinoma espinocelular de la piel que haya recibido un tratamiento potencialmente curativo o el cáncer de cuello uterino in situ.
    6. Presentar metástasis activas en el sistema nervioso central (SNC) o meningitis carcinomatosa. Los pacientes con metástasis cerebrales tratadas con anterioridad podrán participar siempre que se encuentren estables (sin signos de progresión en los estudios de imagen durante al menos cuatro semanas antes de la primera dosis del tratamiento del ensayo y con retorno de todos los síntomas neurológicos a la situación basal), no presenten indicios de metástasis cerebrales nuevas o que estén aumentando de tamaño y no utilicen esteroides durante al menos 7 días antes de recibir el tratamiento del ensayo. Esta excepción no se aplica a la meningitis carcinomatosa, que está excluida con independencia de la estabilidad clínica.
    7.Padecer una enfermedad autoinmunitaria que haya necesitado tratamiento sistémico en los dos años precedentes (es decir, fármacos modificadores de la enfermedad, corticosteroides o inmunodepresores). El tratamiento de reposición (p. ej., tiroxina, insulina o corticosteroides en dosis fisiológicas para una insuficiencia suprarrenal o hipofisaria, etc.) no se considera una forma de tratamiento sistémico.
    8.Tener un diagnóstico de inmunodeficiencia o haber recibido corticoterapia sistémica o algún tipo de tratamiento inmunodepresor en los 7 días previos a la administración de la primera dosis del tratamiento del ensayo. El uso de dosis fisiológicas de corticosteroides podrá autorizarse previa consulta con el promotor.
    9.Presentar antecedentes o signos de neumopatía intersticial o de neumonitis no infecciosa activa.
    10. Presentar una infección activa con necesidad de tratamiento sistémico.
    11.Tener antecedentes o indicios actuales de cualquier enfermedad o situación (p. ej., carencia conocida de la enzima dihidropirimidina deshidrogenasa [DPD]), tratamiento o anomalía analítica que pueda confundir los resultados del ensayo, dificultar la participación del paciente durante todo el estudio o motivar que la participación en el ensayo no sea lo mejor para el paciente, en opinión del investigador responsable del tratamiento.
    12.Presentar un trastorno psiquiátrico o por abuso de sustancias que podría dificultar el cumplimiento de los requisitos del ensayo.
    13.Estar embarazada o en período de lactancia o tener intención de concebir o engendrar un hijo durante el período previsto del ensayo, desde la visita de selección hasta 180 días después de la última dosis del tratamiento del estudio.
    14.Haber recibido tratamiento con un fármaco anti PD 1, anti PD L1 o anti PD L2
    15.Tener antecedentes de infección por el virus de la inmunodeficiencia humana (VIH) (anticuerpos contra el VIH 1 o 2).
    16.Tener hepatitis B activa demostrada (por ejemplo, reactividad del HBsAg) o hepatitis C demostrada (por ejemplo, detección [cualitativa] de ARN del VHC).
    17.Estar participando o haber participado en un estudio de un fármaco o producto sanitario en investigación y estar recibiendo o haber recibido el tratamiento o producto sanitario en investigación en las 4 semanas anteriores a la primera dosis del tratamiento del estudio.
    18. Haber recibido una vacuna de microorganismos vivos en los 30 días previos al comienzo previsto del tratamiento del ensayo.
    Nota: Las vacunas contra la gripe estacional inyectables contienen, por lo general, virus inactivados y se permite su uso; en cambio, las vacunas antigripales intranasales (por ejemplo, Flu Mist®) son vacunas de virus vivos atenuados y no se permite su uso.
    19.Formar parte, o tener un familiar directo (por ejemplo, cónyuge, padre/madre o tutor legal, hermano o hijo) que forme parte del personal del centro del estudio o del promotor implicado directamente en este ensayo, salvo dictamen prospectivo del CEIC (presidente o persona designada) que autorice la excepción a este criterio para un paciente concreto.
    E.5 End points
    E.5.1Primary end point(s)
    Efficacy Endpoints
    This trial (MK3475-062) will use a dual endpoint of OS and PFS. PFS is an acceptable scientific endpoint for a randomized Phase III trial to demonstrate superiority of a new antineoplastic therapy. RECIST 1.1 will be used to determine the dates of progression as this methodology is accepted by regulatory authorities. Because the treatment assignment is unblinded for pembrolizumab monotherapy, images will be read by central radiologists blinded to treatment assignment to minimize bias in the response.

    RECIST 1.1 as assessed by the central vendor will be used as the primary PFS efficacy endpoint. Standard RECIST 1.1 will be used by the local site for treatment decisions until verification of PD by the central imaging vendor. Following verification of PD by central vendor, treatment decision may be made by the adaptation of RECIST 1.1, termed immune-related RECIST (irRECIST )
    El ensayo clinico (MK3475-062) utilizará un criterio de valoración doble de la SG y la SSP. La SSP es un criterio de valoración científico aceptable para un estudio de fase III aleatorizado que pretenda demostrar la superioridad de un nuevo tratamiento antineoplásico. Se aplicarán los criterios RECIST 1.1 para determinar las fechas de progresión, por tratarse de una metodología aceptada por las autoridades sanitarias. Dado que la asignación del tratamiento será desenmascarada para pembrolizumab en monoterapia, las imágenes serán interpretadas de forma centralizada por radiólogos que desconocerán el tratamiento asignado con el fin de reducir al mínimo el sesgo en la respuesta.
    Las respuestas RECIST 1.1 evaluadas por el proveedor central se emplearán como criterio de valoración principal de la eficacia en la SSP. El centro local utilizará los criterios RECIST 1.1 convencionales para las decisiones sobre el tratamiento hasta la verificación de la PE por el laboratorio de imagen central. Tras la verificación de la PE por el proveedor central, las decisiones sobre el tratamiento se tomarán adaptando los criterios RECIST 1.1, tal como se describe en la sección 7.1.2.6.2.1, RECIST relacionados con la inmunidad (irRECIST)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Response will be assessed throughout the study. The first protocol defined response assessment is scheduled for Week 6, with additional assessments following at 6 week intervals.
    La respuesta será evaluada durante todo el estudio. La primera evaluación de la respuesta que el protocolo define está programada para la semana 6, con evaluaciones adicionales siguientes a intervalos de 6 semanas
    E.5.2Secondary end point(s)
    Safety Endpoints
    The safety objective of this trial is to characterize the safety and tolerability of pembrolizumab monotherapy and in combination therapy in subjects with gastric or GEJ adenocarcinoma. The safety analysis will be based on subjects who experienced toxicities as defined by CTCAE criteria. Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received study treatments, including serious adverse events (SAEs) and events of clinical interest (ECIs).

    Safety will be assessed by reported adverse experiences using CTCAE, Version 4.0. The attribution to drug, time-of-onset, duration of the event, its resolution, and any concomitant medications administered will be recorded. AEs will be analyzed including but not limited to all AEs, SAEs, fatal AEs, and laboratory changes.
    El objetivo de seguridad de este estudio es caracterizar la seguridad y tolerabilidad de pembrolizumab en monoterapia y en combinación en pacientes con adenocarcinoma gástrico o de la UGE. El análisis de la seguridad se basará en los pacientes que experimenten reacciones adversas, definidas conforme a los CTCAE. La seguridad se evaluará cuantificando las reacciones adversas y sus grados que experimenten los pacientes que reciban tratamientos del estudio, lo que incluirá los acontecimientos adversos graves (AAG) y los acontecimientos de interés clínico (AIC).
    La seguridad se valorará mediante los acontecimientos adversos notificados empleando los CTCAE, versión 4.0. Se consignará la atribución de relación causal con el fármaco, el momento de aparición, la duración del acontecimiento, su resolución y los medicamentos concomitantes administrados. Los AA analizados serán, entre otros, todos los AA, AAG, AA mortales y variaciones de los parámetros analíticos. Además, se recopilarán los acontecimientos adversos inmunitarios (AAi) específicos, que se considerarán acontecimientos de interés clínico (AIC) inmunitarios
    E.5.2.1Timepoint(s) of evaluation of this end point
    Safety will be assessed at all study visits conducted either in person or by phone.
    La seguridad se evaluara en todas las visitas de estudio realizadas ya sea en persona o por teléfono.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Partial blind: MK3475 monotherapy open label.MK3475/PBO double blind in combi treatment arms
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA61
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Austria
    Brazil
    Chile
    Colombia
    Czech Republic
    France
    Germany
    Guatemala
    Hong Kong
    Hungary
    Ireland
    Italy
    Japan
    Korea, Democratic People's Republic of
    Latvia
    Lithuania
    Mexico
    Netherlands
    New Zealand
    Poland
    Portugal
    Puerto Rico
    Romania
    Russian Federation
    South Africa
    Spain
    Sweden
    Switzerland
    Taiwan
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The overall trial ends when the last subject completes the last study-related phone-call or visit, discontinues from the trial or is lost to follow-up (i.e. the subject is unable to be contacted by the investigator).
    El ensayo en su conjunto finalizará cuando el último paciente complete la última llamada telefónica o visita del estudio, se retire del ensayo o se pierda para el seguimiento (es decir, cuando el investigador no pueda ponerse en contacto con el paciente).
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 600
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 150
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state42
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 258
    F.4.2.2In the whole clinical trial 750
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The protocol does not include any plans for treatment or care following completion of the protocol.

    Discontinuation of treatment may be considered for subjects who have attained a confirmed CR. Subjects who then experience disease progression may be eligible for up to one year of additional treatment with pembrolizumab via the Second Course Phase at the discretion of the investigator if no cancer treatment was administered since the last dose of pembrolizumab.
    El protocolo no incluye ningún plan de tratamiento o mantenimiento una vez finalizado. La suspensión del tratamiento será considerada para pacientes que hayan tenido una RC confirmada. Los pacientes que posteriormente experimenten progresión de la enfermedad podrán recibir hasta un año de tratamiento adicional con pembrolizumab, en la fase del segundo ciclo, a discreción del investigador, siempre que no hayan recibido ningún tratamiento para el cáncer desde la última dosis de pembrolizumab.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation Quintiles Laboratories Europe
    G.4.3.4Network Country United Kingdom
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-09-16
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-09-14
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2022-06-06
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 06:19:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA